|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GSK3A |
Gene summary for GSK3A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GSK3A | Gene ID | 2931 |
| Gene name | glycogen synthase kinase 3 alpha | |
| Gene Alias | GSK3A | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | A0A024R0L5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2931 | GSK3A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.84e-09 | 1.58e-01 | 0.0155 |
| 2931 | GSK3A | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.13e-13 | 3.51e-01 | -0.1808 |
| 2931 | GSK3A | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.26e-09 | 2.84e-01 | -0.0811 |
| 2931 | GSK3A | HTA11_78_2000001011 | Human | Colorectum | AD | 2.14e-07 | 1.99e-01 | -0.1088 |
| 2931 | GSK3A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.97e-12 | 2.30e-01 | -0.1954 |
| 2931 | GSK3A | HTA11_411_2000001011 | Human | Colorectum | SER | 4.21e-05 | 4.02e-01 | -0.2602 |
| 2931 | GSK3A | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.40e-07 | 4.17e-01 | -0.2196 |
| 2931 | GSK3A | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.43e-09 | 2.84e-01 | -0.1207 |
| 2931 | GSK3A | HTA11_83_2000001011 | Human | Colorectum | SER | 7.70e-11 | 2.99e-01 | -0.1526 |
| 2931 | GSK3A | HTA11_696_2000001011 | Human | Colorectum | AD | 1.54e-14 | 3.39e-01 | -0.1464 |
| 2931 | GSK3A | HTA11_866_2000001011 | Human | Colorectum | AD | 2.19e-05 | 2.24e-01 | -0.1001 |
| 2931 | GSK3A | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.21e-17 | 3.69e-01 | -0.059 |
| 2931 | GSK3A | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.05e-09 | 5.10e-01 | -0.1706 |
| 2931 | GSK3A | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.06e-04 | 2.01e-01 | -0.2061 |
| 2931 | GSK3A | HTA11_546_2000001011 | Human | Colorectum | AD | 1.33e-04 | 2.09e-01 | -0.0842 |
| 2931 | GSK3A | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.18e-02 | 2.95e-01 | -0.00410000000000005 |
| 2931 | GSK3A | HTA11_866_3004761011 | Human | Colorectum | AD | 2.56e-08 | 2.03e-01 | 0.096 |
| 2931 | GSK3A | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.99e-03 | 2.74e-01 | 0.0131 |
| 2931 | GSK3A | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.35e-02 | 1.90e-01 | -0.0177 |
| 2931 | GSK3A | HTA11_6801_2000001011 | Human | Colorectum | SER | 7.09e-04 | 3.23e-01 | 0.0171 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0070997110 | Oral cavity | LP | neuron death | 135/4623 | 361/18723 | 4.31e-08 | 1.52e-06 | 135 |
| GO:0051348110 | Oral cavity | LP | negative regulation of transferase activity | 106/4623 | 268/18723 | 4.60e-08 | 1.61e-06 | 106 |
| GO:0032436110 | Oral cavity | LP | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 46/4623 | 90/18723 | 5.83e-08 | 1.99e-06 | 46 |
| GO:001082118 | Oral cavity | LP | regulation of mitochondrion organization | 65/4623 | 144/18723 | 6.61e-08 | 2.24e-06 | 65 |
| GO:190305218 | Oral cavity | LP | positive regulation of proteolysis involved in cellular protein catabolic process | 61/4623 | 133/18723 | 8.17e-08 | 2.72e-06 | 61 |
| GO:000863719 | Oral cavity | LP | apoptotic mitochondrial changes | 51/4623 | 107/18723 | 2.07e-07 | 6.33e-06 | 51 |
| GO:000756819 | Oral cavity | LP | aging | 125/4623 | 339/18723 | 3.29e-07 | 9.62e-06 | 125 |
| GO:000042215 | Oral cavity | LP | autophagy of mitochondrion | 41/4623 | 81/18723 | 4.23e-07 | 1.21e-05 | 41 |
| GO:006172615 | Oral cavity | LP | mitochondrion disassembly | 41/4623 | 81/18723 | 4.23e-07 | 1.21e-05 | 41 |
| GO:0010563110 | Oral cavity | LP | negative regulation of phosphorus metabolic process | 153/4623 | 442/18723 | 1.47e-06 | 3.53e-05 | 153 |
| GO:2000060110 | Oral cavity | LP | positive regulation of ubiquitin-dependent protein catabolic process | 49/4623 | 107/18723 | 1.57e-06 | 3.72e-05 | 49 |
| GO:1901214110 | Oral cavity | LP | regulation of neuron death | 115/4623 | 319/18723 | 3.39e-06 | 7.19e-05 | 115 |
| GO:1901216110 | Oral cavity | LP | positive regulation of neuron death | 44/4623 | 97/18723 | 7.13e-06 | 1.37e-04 | 44 |
| GO:005105213 | Oral cavity | LP | regulation of DNA metabolic process | 125/4623 | 359/18723 | 9.43e-06 | 1.75e-04 | 125 |
| GO:005140218 | Oral cavity | LP | neuron apoptotic process | 91/4623 | 246/18723 | 1.07e-05 | 1.94e-04 | 91 |
| GO:190332215 | Oral cavity | LP | positive regulation of protein modification by small protein conjugation or removal | 57/4623 | 138/18723 | 1.24e-05 | 2.23e-04 | 57 |
| GO:001082214 | Oral cavity | LP | positive regulation of mitochondrion organization | 35/4623 | 74/18723 | 1.99e-05 | 3.34e-04 | 35 |
| GO:004690216 | Oral cavity | LP | regulation of mitochondrial membrane permeability | 31/4623 | 63/18723 | 2.20e-05 | 3.58e-04 | 31 |
| GO:190353314 | Oral cavity | LP | regulation of protein targeting | 37/4623 | 81/18723 | 3.07e-05 | 4.74e-04 | 37 |
| GO:0043434110 | Oral cavity | LP | response to peptide hormone | 138/4623 | 414/18723 | 4.00e-05 | 5.87e-04 | 138 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa04728 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
| hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa047281 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
| hsa049322 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa047282 | Colorectum | SER | Dopaminergic synapse | 37/1580 | 132/8465 | 5.27e-03 | 3.28e-02 | 2.38e-02 | 37 |
| hsa049323 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa047283 | Colorectum | SER | Dopaminergic synapse | 37/1580 | 132/8465 | 5.27e-03 | 3.28e-02 | 2.38e-02 | 37 |
| hsa049324 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
| hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa047284 | Colorectum | MSS | Dopaminergic synapse | 45/1875 | 132/8465 | 1.02e-03 | 5.94e-03 | 3.64e-03 | 45 |
| hsa049325 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
| hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa047285 | Colorectum | MSS | Dopaminergic synapse | 45/1875 | 132/8465 | 1.02e-03 | 5.94e-03 | 3.64e-03 | 45 |
| hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GSK3A | SNV | Missense_Mutation | c.430N>G | p.Leu144Val | p.L144V | P49840 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| GSK3A | SNV | Missense_Mutation | rs750207489 | c.757N>A | p.Asp253Asn | p.D253N | P49840 | protein_coding | tolerated(0.54) | benign(0.286) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| GSK3A | SNV | Missense_Mutation | c.710N>T | p.Ser237Phe | p.S237F | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| GSK3A | SNV | Missense_Mutation | c.758N>G | p.Asp253Gly | p.D253G | P49840 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
| GSK3A | insertion | Frame_Shift_Ins | novel | c.1322_1323insTACAGGCGTGAAC | p.Pro442ThrfsTer26 | p.P442Tfs*26 | P49840 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| GSK3A | insertion | Frame_Shift_Ins | novel | c.1320_1321insCCGCTTGGCCTCCTAAAGTGTTGGG | p.Ile441ProfsTer31 | p.I441Pfs*31 | P49840 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| GSK3A | SNV | Missense_Mutation | novel | c.787N>A | p.Asp263Asn | p.D263N | P49840 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GSK3A | SNV | Missense_Mutation | novel | c.616G>C | p.Ala206Pro | p.A206P | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| GSK3A | SNV | Missense_Mutation | novel | c.288C>A | p.Asp96Glu | p.D96E | P49840 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| GSK3A | SNV | Missense_Mutation | c.1264N>G | p.Leu422Val | p.L422V | P49840 | protein_coding | deleterious(0) | benign(0.377) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Thiadiazolidindione derivative 2 | |||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PMID27828716-Compound-BIO-acetoxime | |||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | CHIR-99021 | CHIR-99021 | ||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | inhibitor | 249565696 | ||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PHA-767491 | CHEMBL225519 | ||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | AR-A014418 | CHEMBL259850 | ||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | KENPAULLONE | KENPAULLONE | ||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PMID27828716-Compound-17 | |||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Maleimides derivative 3 | |||
| 2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Indazole derivative 6 |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |